ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

NCT06714357 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

130

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG: irinotecan
DRUG: panitumumab
DRUG: Valproic Acid (VPA)

Sponsor

National Cancer Institute, Naples